Allergan (NYSE:AGN) had a busy, and occasionally fraught, 2017.
After the company inked a controversial deal with a Native American tribe to shield its Restasis patents from review, a federal judge in Texas invalidated the IP, helping to clear the way for generics. And just last week, Allergan announced that it would slash 1,400 jobs in an effort to cut costs.
But looking ahead to the new year, chairman and chief executive Brent Saunders seems optimistic.
Get the full story at our sister site, Drug Delivery Business News.
The post Allergan talks taxes and competition in 2018 outlook appeared first on MassDevice.
from MassDevice http://ift.tt/2CLb9gx
Cap comentari:
Publica un comentari a l'entrada